Activities of the newer antibiotics against gram-negative resistant organisms.
AB
top of page
Sepsis & Septic Shock
Public·298 members
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
In a phase 3, double-blind, noninferiority trial, ceftobiprole's effectiveness was compared with daptomycin for treating complicated Staphylococcus aureus bacteremia, including the methicillin-resistant strains. The study population comprised 390 patients, 387 of whom had confirmed S. aureus bacteremia. The primary outcome was to determine overall treatment success 70 days post-randomization. Both drugs demonstrated comparable effectiveness, with ceftobiprole proving to be noninferior to daptomycin. Notably, the occurrence of adverse events was similar between the two treatment groups, although gastrointestinal issues, primarily mild nausea, appeared more frequent in the ceftobiprole group.
AB
Probiotics in AKI and Sepsis: A Clinical Insight
During acute kidney injury (AKI) stemming from sepsis, a dysbiotic change in the intestinal microbiota is observed, impacting kidney function recovery. To evaluate the therapeutic potential of probiotics in alleviating this dysbiosis and potentially enhancing kidney function recovery, a double-blind clinical trial was conducted. 92 patients with sepsis-associated AKI were treated with either probiotics or a placebo for one week. The primary outcomes investigated were kidney function recovery and mortality at 6 months, while secondary outcomes included markers like urea, urine volume, need for kidney replacement therapy, and any adverse events. The study found no significant benefits of probiotics in improving KFR or reducing 6-month mortality. However, a notable reduction in urea levels was observed in the probiotics group.
DA
For those who did not witness the start of the HIV pandemic, this was the first report!
And here is the progress made in relation to antiretroviral medications (ART) over the past 40 years or so!
DA
SB
DA
bottom of page